Three GLP-1 analogs with potential therapeutic value in AD (Corbett et al., 2012; Hölscher, 2014), have shown in vivo benefits in mouse AD models (Gengler et al., 2012). This evidence concerns the gene GLP1R and Alzheimer disease.